MoS announces Rs.720 Crore Quantum Fabrication facilities at IIT Bombay (See 'Corp Brief') India, Afghanistan to deepen cooperation in Textile Sector (See 'Corp Brief') MoS lauds Quantum sensing breakthroughs by IIT, inaugurates first Liquid Helium Cryogenic facility (See 'Corp Brief') Evidence-Based Ayurvedic Products are Future of Wellness: Jadhav (See 'Corp Brief') Hotel, Industry & farmers partnerships is Critical for mutual growth: Agri Secy (See 'Corp Brief') MeitY launches Cyber Security Innovation Challenge (See 'Corp Brief') India-Oman Joint Military Cooperation Committee meeting held in New Delhi (See 'Corp Brief') A&C - Once right to file written statement is closed, application under Section 8 of Arbitration and Conciliation Act seeking reference to arbitration is not maintainable: HC (See 'Legal Desk') 'Workers are the miners of nation-building': Sonowal (See 'Corp Brief') India strengthens Textile and Sericulture Cooperation with Georgia (See 'Corp Brief') J&K to host launch of First Limestone Block Auction Roadshow (See 'Corp Brief') Indian Railways crosses 1 Billion Tonne Freight Loading in FY 25-26 (See 'Corp Brief') FEMA - Indian currency falls within scope of 'property' u/s 63 of FERA, empowering authorities to confiscate it when used in contravention of law: HC (See 'Legal Desk') IICA, DGR conclude Certification Program for senior Defence Officers (See 'Corp Brief') Op Drishti: Over 400 surgeries performed at Northern Command, J&K (See 'Corp Brief') ILO welcomes India's Labour Codes (See 'Corp Brief') Limitation Act - provisions of Limitation Act cannot be applied beneficially in favor of a petitioner who demonstrates mala fide intentions, including tampering with official documents: HC (See 'Legal Desk') PMLA - Pre-arrest protection would undermine integrity of ongoing investigation, and anticipatory bail in such cases should be granted sparingly: HC (See 'Legal Desk') RTI/SEBI - Refusal to disclose certain information justified, where details sought for pertains to commercial interests of third parties & received by SEBI in fiduciary capacity during its regulatory functions & disclosure of which could harm competitive position of relevant entities - YES: SEBI (See 'Legal Desk') Misc - When election process was initiated by notifying election and subsequently commenced, writ petition is not maintainable against it without exhausting alternate remedy: HC (See 'Legal Desk') PMLA - Question of substitution of attached property by way of any cash deposit or fixed deposit does not arise, if said property directly/indirectly acquired are attached, but not attached as value thereof: SAFEMA (See 'Legal Desk') Government intervention and Corporate governance (See CORP EINSICHT)

Print

Evidence-Based Ayurvedic Products are Future of Wellness: Jadhav

Published: Nov 25, 2025

By TIOLCorplaws News Service

NEW DELHI, NOV 25, 2025: THE Central Council for Research in Ayurvedic Sciences (CCRAS), Ministry of Ayush, is set to unveil the second edition of its high-impact industry-research interface programme, SIDDHI 2.0 (Scientific Innovation in Drug Development, Healthcare & Integration), in Vijayawada on November 25-26, 2025. Organised by CCRAS-Regional Ayurveda Research Institute (RARI), Vijayawada, in collaboration with the Confederation of Indian Industry (CII), Vijayawada Zone, the conclave is positioned as one of the most significant national platforms advancing the scientific, industrial, and commercial ecosystem of Ayurveda.

Ahead of the launch, Prataprao Jadhav, Union Minister of State (IC) for Ayush and Minister of State for Health & Family Welfare, Government of India, mentioned, "SIDDHI 2.0 represents our continuous efforts and commitment to boost the Traditional Medicine sector and transform Ayush into a system that stands firmly on scientific foundations. CCRAS has created a strong national platform for innovation, and its engagement with industry is crucial for transforming research outcomes into high-quality Ayurvedic products that meet global expectations."

Vaidya Rajesh Kotecha, Secretary, Ministry of Ayush, emphasised, "Ayurveda's future lies in its ability to convert validated research into accessible and reliable solutions. SIDDHI 2.0 is a timely initiative that brings together CCRAS' scientific strength and the manufacturing capabilities of India's Ayush industry, enabling faster product development and smoother regulatory pathways."

Building on the momentum generated by CCRAS' PRAGATI-2024 (Pharma Research in Ayurgan and Techno Innovation) initiative last year, SIDDHI 2.0 marks a decisive shift towards research-led product development, indigenous technologies, and faster translational pipelines-priorities at the heart of India's current Ayush innovation strategy.

Prof. Rabinarayan Acharya, Director General, CCRAS, highlighted the key features of the program and informed, "This two-day programme has been structured as a focused engagement that aligns CCRAS' scientific work with industrial application. It will showcase CCRAS' research outcomes, match them with industry requirements, and create actionable pathways for product development, validation, and scale-up. By bringing researchers, manufacturers, regulators, and clinicians together, the programme will accelerate Ayurveda's transition toward a more evidence-driven, innovation-ready future."

The initiative is being driven by the scientific leadership of CCRAS, which has articulated a strong national vision for evidence-based Ayurveda. CCRAS is poised to outline India's rapidly evolving Ayurvedic research ecosystem, playing a central role in drug development, standardisation, validation, regulatory advancement, and commercialisation.

The event, SIDDHI 2.0, will be graced by K. Dinesh Kumar, IAS, Director (Ayush), Government of Andhra Pradesh, and Dr. N. Srikanth, Deputy Director General, CCRAS. The meet will also bring together over 25 leading Ayurvedic pharmaceutical companies from Southern India-including Himalaya, Oushadhi, IMPCOPS, Laila Nutra Pvt. Ltd., and Imis Pharmaceuticals-along with researchers, clinicians, academic experts, State Ayush representatives, and postgraduate scholars from NRS Ayurvedic College, Vijayawada.

Positioned as a national translational accelerator, SIDDHI 2.0 aims to expand industry adoption of CCRAS technologies, strengthen institutional networks, enhance quality and regulatory systems, and support the development of globally competitive Ayurvedic pharmaceuticals. By advancing scientific innovation and industrial collaboration in tandem, SIDDHI 2.0 sets the stage for a new era of evidence-based Ayurveda aligned with India's vision for holistic, modern, and scalable traditional medicine.

TIOL CORP SEARCH

TIOL GROUP WEBSITES

taxindiaonline
taxindiainternational
tioltube
TKF
TIOLawards
A TIOL Website. Copyright © 2025 TIOLcorplaws.com All rights reserved.